

Inti Zlobec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/833269/publications.pdf>

Version: 2024-02-01

209
papers

14,382
citations

26630

56
h-index

24258

110
g-index

213
all docs

213
docs citations

213
times ranked

21164
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on the current opinion, status and future development of digital pathology in Switzerland in light of COVID-19. <i>Journal of Clinical Pathology</i> , 2022, 75, 687-689.	2.0	12
2	Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer. <i>Modern Pathology</i> , 2022, 35, 240-248.	5.5	9
3	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	2.6	7
4	Self-rule to multi-adapt: Generalized multi-source feature learning using unsupervised domain adaptation for colorectal cancer tissue detection. <i>Medical Image Analysis</i> , 2022, 79, 102473.	11.6	11
5	Towards a national strategy for digital pathology in Switzerland. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 647-652.	2.8	7
6	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. <i>Neuroendocrinology</i> , 2021, 111, 883-894.	2.5	54
7	Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups. <i>Modern Pathology</i> , 2021, 34, 222-232.	5.5	27
8	Taking tumour budding to the next frontier â€” a post International Tumour Budding Consensus Conference (ITBCC) 2016 review. <i>Histopathology</i> , 2021, 78, 476-484.	2.9	20
9	Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 719-726.	2.8	3
10	Tumour budding and CD8 ⁺ T cells: â€”attackersâ€” and â€”defendersâ€” in rectal cancer with and without neoadjuvant chemoradiotherapy. <i>Histopathology</i> , 2021, 78, 1009-1018.	2.9	6
11	Tumour budding in solid cancers. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 101-115.	27.6	166
12	Classification of Intestinal Gland Cell-Graphs Using Graph Neural Networks. , 2021, , .		5
13	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
14	Investigating new serological and tissue markers for the follow-up of patients operated for alveolar echinococcosis. <i>Parasite Immunology</i> , 2021, 43, e12827.	1.5	8
15	Improving tumor budding reporting in colorectal cancer: a Delphi consensus study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 459-469.	2.8	28
16	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. <i>Sarcoma</i> , 2021, 2021, 1-12.	1.3	4
17	Refining the ITBCC tumor budding scoring system with a â€”zero-buddingâ€” category in colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1085-1090.	2.8	12
18	Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3118-3118.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Molecular and Histological Profiling Reveals an Innate-Shaped Immune Microenvironment in Solitary Juvenile Polyps. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00361.	2.5	1
20	Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1. <i>Molecular Oncology</i> , 2021, 15, 2782-2800.	4.6	19
21	LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 749.	2.5	23
22	RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. <i>Pathology Research and Practice</i> , 2021, 223, 153486.	2.3	5
23	Combined Simplified Molecular Classification of Gastric Adenocarcinoma, Enhanced by Lymph Node Status: An Integrative Approach. <i>Cancers</i> , 2021, 13, 3722.	3.7	7
24	Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods. <i>Scientific Reports</i> , 2021, 11, 2371.	3.3	9
25	Tutorial: methods for three-dimensional visualization of archival tissue material. <i>Nature Protocols</i> , 2021, 16, 4945-4962.	12.0	7
26	Rhesus Macaque CODEX Multiplexed Immunohistochemistry Panel for Studying Immune Responses During Ebola Infection. <i>Frontiers in Immunology</i> , 2021, 12, 729845.	4.8	7
27	Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score. <i>Histopathology</i> , 2020, 76, 572-580.	2.9	19
28	ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics. <i>Cell Death and Differentiation</i> , 2020, 27, 1965-1980.	11.2	20
29	Validation of the International Tumor Budding Consensus Conference (ITBCC) 2016 recommendation in squamous cell carcinoma of the lung—a single-center analysis of 354 cases. <i>Modern Pathology</i> , 2020, 33, 802-811.	5.5	23
30	Current opinion, status and future development of digital pathology in Switzerland. <i>Journal of Clinical Pathology</i> , 2020, 73, 341-346.	2.0	21
31	The battle for prognosis at the invasive front of colorectal cancer. <i>EBioMedicine</i> , 2020, 58, 102918.	6.1	7
32	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> , 2020, 182, 1341-1359.e19.	28.9	464
33	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	1.6	130
34	Editorial: Computational Pathology. <i>Frontiers in Medicine</i> , 2020, 7, 245.	2.6	3
35	Tumour budding and its clinical implications in gastrointestinal cancers. <i>British Journal of Cancer</i> , 2020, 123, 700-708.	6.4	36
36	Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients. <i>European Journal of Cancer</i> , 2020, 130, 139-145.	2.8	12

#	ARTICLE	IF	CITATIONS
37	Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. <i>ELife</i> , 2020, 9, .	6.0	18
38	Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 227-227.	1.6	0
39	An Effective Deep Learning Architecture Combination for Tissue Microarray Spots Classification of H&E Stained Colorectal Images. , 2020, , .		4
40	Cell Line Derived Xenograft Mouse Models Are a Suitable in vivo Model for Studying Tumor Budding in Colorectal Cancer. <i>Frontiers in Medicine</i> , 2019, 6, 139.	2.6	24
41	Oncologic long-term outcomes of emergency versus elective resection for colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 2091-2099.	2.2	31
42	TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells. <i>Molecular Oncology</i> , 2019, 13, 2393-2405.	4.6	32
43	Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung – A Single Center Analysis of 354 Cases. <i>Frontiers in Medicine</i> , 2019, 6, 196.	2.6	12
44	The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. <i>Mucosal Immunology</i> , 2019, 12, 990-1003.	6.0	107
45	A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. <i>Cell</i> , 2019, 177, 572-586.e22.	28.9	107
46	Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma. <i>Human Pathology</i> , 2019, 87, 18-27.	2.0	28
47	Prospective Validation of Facial Nerve Monitoring to Prevent Nerve Damage During Robotic Drilling. <i>Frontiers in Surgery</i> , 2019, 6, 58.	1.4	8
48	Evaluation of Tumor Budding in Primary Colorectal Cancer and Corresponding Liver Metastases Based on H&E and Pancytokeratin Staining. <i>Frontiers in Medicine</i> , 2019, 6, 247.	2.6	16
49	Synaptic proximity enables NMDAR signalling to promote brain metastasis. <i>Nature</i> , 2019, 573, 526-531.	27.8	320
50	Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. <i>Human Pathology</i> , 2019, 85, 145-151.	2.0	51
51	Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2019, 18, e20-e38.	2.3	62
52	A Digital Pathology-Based Shotgun-Proteomics Approach to Biomarker Discovery in Colorectal Cancer. <i>Journal of Pathology Informatics</i> , 2019, 10, 40.	1.7	2
53	Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. <i>Histopathology</i> , 2018, 73, 137-146.	2.9	27
54	Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. <i>Clinical Cancer Research</i> , 2018, 24, 4444-4454.	7.0	132

#	ARTICLE	IF	CITATIONS
55	GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth. <i>Cancer Cell</i> , 2018, 33, 736-751.e5.	16.8	53
56	Tumour budding in colorectal cancer: molecular rationale for clinical translation. <i>Nature Reviews Cancer</i> , 2018, 18, 203-204.	28.4	55
57	Expression Patterns of TNF±, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 347-354.	1.3	44
58	Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas. <i>Surgical Oncology</i> , 2018, 27, 100-105.	1.6	12
59	Impact of the Microenvironment on Tumour Budding in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 101-111.	1.6	6
60	CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. <i>Clinical Epigenetics</i> , 2018, 10, 120.	4.1	41
61	Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?. <i>Frontiers in Medicine</i> , 2018, 5, 234.	2.6	65
62	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. <i>British Journal of Cancer</i> , 2018, 119, 1244-1251.	6.4	57
63	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	13.7	1,487
64	Next-generation tissue microarrays (ngTMA) in translational research. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 2, 58.	0.1	1
65	Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. <i>Histopathology</i> , 2017, 70, 1044-1051.	2.9	32
66	Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 58-70.	3.0	35
67	DNA profiling of tumor buds in colorectal cancer indicates that they have the same mutation profile as the tumor from which they derive. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 341-346.	2.8	14
68	Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. <i>Oncolmmunology</i> , 2017, 6, e1288330.	4.6	11
69	Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. <i>Modern Pathology</i> , 2017, 30, 1299-1311.	5.5	652
70	Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 777-786.	4.2	20
71	CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2017, 214, 359-380.	8.5	125
72	Low co-expression of epidermal growth factor receptor and its chaperone heat shock protein 90 is associated with worse prognosis in primary glioblastoma, IDH-wild-type. <i>Oncology Reports</i> , 2017, 38, 2394-2400.	2.6	5

#	ARTICLE	IF	CITATIONS
73	Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 171-178.	3.0	30
74	Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer. <i>Cell Reports</i> , 2017, 21, 3190-3204.	6.4	167
75	TREM-1 promotes intestinal tumorigenesis. <i>Scientific Reports</i> , 2017, 7, 14870.	3.3	41
76	The ESRP1-GPR137 axis contributes to intestinal pathogenesis. <i>ELife</i> , 2017, 6, .	6.0	24
77	Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1640.	4.1	11
78	The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. <i>Oncotarget</i> , 2017, 8, 70617-70629.	1.8	48
79	Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer. <i>Oncotarget</i> , 2017, 8, 54604-54615.	1.8	45
80	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	8.1	227
81	PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. <i>European Journal of Cancer</i> , 2016, 65, 80-90.	2.8	18
82	Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 113-124.	3.0	18
83	Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report. <i>Digestive and Liver Disease</i> , 2016, 48, 1378-1385.	0.9	5
84	Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. <i>Oncolmmunology</i> , 2016, 5, e1106677.	4.6	99
85	Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas. <i>Human Pathology</i> , 2016, 52, 1-8.	2.0	31
86	Tumor budding in colorectal cancer—ready for diagnostic practice?. <i>Human Pathology</i> , 2016, 47, 4-19.	2.0	186
87	The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. <i>Oncolmmunology</i> , 2016, 5, e1062966.	4.6	80
88	Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 279.	4.4	47
89	Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device. <i>Microarrays (Basel, Switzerland)</i> , 2015, 4, 188-195.	1.4	2
90	Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer. <i>Radiation Oncology</i> , 2015, 10, 240.	2.7	23

#	ARTICLE	IF	CITATIONS
91	Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 485-493.	2.8	94
92	CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. <i>Leukemia Research</i> , 2015, 39, 749-756.	0.8	48
93	Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin. <i>Histopathology</i> , 2015, 67, 464-473.	2.9	19
94	Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. <i>BMC Cancer</i> , 2015, 15, 160.	2.6	48
95	High tumor budding stratifies breast cancer with metastatic properties. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 363-371.	2.5	62
96	Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. <i>Translational Research</i> , 2015, 166, 207-217.	5.0	43
97	Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. <i>Human Pathology</i> , 2015, 46, 1573-1581.	2.0	36
98	Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. <i>Histopathology</i> , 2015, 66, 715-725.	2.9	20
99	TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 874-885.	1.8	64
100	Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 4190-4201.	1.8	52
101	DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells. <i>Oncotarget</i> , 2015, 6, 36774-36788.	1.8	14
102	VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 41453-41463.	1.8	22
103	High Frequency of CD8 Positive Lymphocyte Infiltration Correlates with Lack of Lymph Node Involvement in Early Rectal Cancer. <i>Disease Markers</i> , 2014, 2014, 1-7.	1.3	16
104	Tumor Budding in Upper Gastrointestinal Carcinomas. <i>Frontiers in Oncology</i> , 2014, 4, 216.	2.8	37
105	The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. <i>Histopathology</i> , 2014, 64, 577-584.	2.9	49
106	Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. <i>International Journal of Cancer</i> , 2014, 134, 2342-2351.	5.1	51
107	Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. <i>Prostate</i> , 2014, 74, 1647-1654.	2.3	17
108	Proper paraffin slide storage is crucial for translational research projects involving immunohistochemistry stains. <i>Clinical and Translational Medicine</i> , 2014, 3, 4.	4.0	43

#	ARTICLE	IF	CITATIONS
109	Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1551-1556.	3.7	52
110	HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker. <i>Neoplasia</i> , 2014, 16, 31-W15.	5.3	99
111	A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 915-921.	1.5	28
112	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	4.5	1,151
113	CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. <i>Journal of Translational Medicine</i> , 2014, 12, 81.	4.4	51
114	A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies. <i>Journal of Visualized Experiments</i> , 2014, , 51893.	0.3	47
115	Tumor budding in the clinical management of colon and rectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 387-403.	0.8	4
116	Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients. <i>Oncotarget</i> , 2014, 5, 4671-4682.	1.8	10
117	Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. <i>Journal of Translational Medicine</i> , 2013, 11, 104.	4.4	65
118	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. <i>Immunity</i> , 2013, 39, 1095-1107.	14.3	112
119	Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. <i>Human Pathology</i> , 2013, 44, 697-705.	2.0	109
120	The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 661-667.	1.6	29
121	Tu1868 PTEN Loss in the Neoplastic Stroma of Pancreatic Ductal Adenocarcinoma (PDAC) Is a Strong Predictor of Distant Metastasis. <i>Gastroenterology</i> , 2013, 144, S-868.	1.3	0
122	Prediction of outcome in patients with low-grade squamous intraepithelial lesions by fluorescence in situ hybridization analysis of human papillomavirus, <i>TERC</i> , and <i>MYC</i> . <i>Cancer Cytopathology</i> , 2013, 121, 423-431.	2.4	5
123	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. <i>European Journal of Cancer</i> , 2013, 49, 2233-2242.	2.8	384
124	Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. <i>Modern Pathology</i> , 2013, 26, 295-301.	5.5	114
125	Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 265.	2.8	29
126	Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naïve prostate cancer and are elevated in castration-resistant disease. <i>Endocrine-Related Cancer</i> , 2013, 20, 403-413.	3.1	43

#	ARTICLE	IF	CITATIONS
127	ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. <i>Nature Communications</i> , 2013, 4, 2130.	12.8	136
128	Novel biomarkers for the prediction of metastasis in colorectal cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 137-146.	1.6	24
129	Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). <i>Journal of Translational Medicine</i> , 2013, 11, 311.	4.4	26
130	High Myeloperoxidase Positive Cell Infiltration in Colorectal Cancer Is an Independent Favorable Prognostic Factor. <i>PLoS ONE</i> , 2013, 8, e64814.	2.5	92
131	The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. <i>Anticancer Research</i> , 2013, 33, 3053-9.	1.1	47
132	Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. <i>Modern Pathology</i> , 2012, 25, 1048-1053.	5.5	70
133	Role of Intra- and Peritumoral Budding in the Interdisciplinary Management of Rectal Cancer Patients. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-6.	0.6	3
134	Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. <i>Journal of Clinical Pathology</i> , 2012, 65, 140-145.	2.0	30
135	Prognostic impact of \hat{I}^2 -2-microglobulin expression in colorectal cancers stratified by mismatch repair status. <i>Journal of Clinical Pathology</i> , 2012, 65, 996-1002.	2.0	36
136	Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. <i>BMC Cancer</i> , 2012, 12, 134.	2.6	77
137	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	4.4	676
138	Stratification and Prognostic Relevance of Jassâ€™s Molecular Classification of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 7.	2.8	17
139	HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. <i>Histopathology</i> , 2012, 60, 397-404.	2.9	82
140	Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: Role of CD24 and CD44 isoforms expression. <i>Breast</i> , 2012, 21, 165-170.	2.2	18
141	Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. <i>Histopathology</i> , 2012, 61, 562-575.	2.9	76
142	The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. <i>Histopathology</i> , 2012, 61, 777-787.	2.9	28
143	Gene Signatures in Colorectal Cancer. , 2012, , 115-136.		2
144	Role of KCNMA1 in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e41664.	2.5	83

#	ARTICLE	IF	CITATIONS
145	Assessing downgrading of locally advanced rectal cancer after chemo-radiotherapy. <i>European Journal of Cancer</i> , 2011, 47, 1125-1126.	2.8	1
146	Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. <i>Human Pathology</i> , 2011, 42, 1888-1896.	2.0	42
147	Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?. <i>Human Pathology</i> , 2011, 42, 702-709.	2.0	9
148	Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. <i>Human Pathology</i> , 2011, 42, 1833-1840.	2.0	89
149	Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. <i>Histopathology</i> , 2011, 58, no-no.	2.9	104
150	Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. <i>Histopathology</i> , 2011, 59, 482-495.	2.9	37
151	High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. <i>Histopathology</i> , 2011, 58, 781-789.	2.9	17
152	High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 741-748.	2.8	20
153	Comprehensive analysis of CpG island methylator phenotype (CIMP) high, low, and negative colorectal cancers based on protein marker expression and molecular features. <i>Journal of Pathology</i> , 2011, 225, 336-343.	4.5	65
154	Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. <i>International Journal of Cancer</i> , 2011, 128, 2663-2672.	5.1	88
155	VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients. <i>Modern Pathology</i> , 2011, 24, 1404-1412.	5.5	20
156	Standardization of whole slide image morphologic assessment with definition of a new application: Digital slide dynamic morphometry. <i>Journal of Pathology Informatics</i> , 2011, 2, 48.	1.7	3
157	Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?. <i>International Journal of Cancer</i> , 2010, 126, 1256-1262.	5.1	156
158	Fluorescence In Situ Hybridization in the Definitive Diagnosis of Malignant Mesothelioma in Effusion Cytology. <i>Chest</i> , 2010, 138, 137-144.	0.8	83
159	Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer. <i>BMC Cancer</i> , 2010, 10, 93.	2.6	16
160	Expression of p16 in lymph node metastases of adjuvantly treated stage III colorectal cancer patients identifies poor prognostic subgroups. <i>Cancer</i> , 2010, 116, 4474-4486.	4.1	14
161	High frequency of tumor-infiltrating FOXP3 ⁺ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. <i>International Journal of Cancer</i> , 2010, 126, 2635-2643.	5.1	287
162	Clinicopathological and protein characterization of BRAF and KRAS mutated colorectal cancer and implications for prognosis. <i>International Journal of Cancer</i> , 2010, 127, 367-380.	5.1	136

#	ARTICLE	IF	CITATIONS
163	Combined analysis of specific <i>KRAS</i> mutation, <i>BRAF</i> and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 2569-2575.	5.1	99
164	Role of tumor size in the pre-operative management of rectal cancer patients. <i>BMC Gastroenterology</i> , 2010, 10, 61.	2.0	9
165	BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma. <i>Histopathology</i> , 2010, 56, 217-228.	2.9	47
166	Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. <i>Histopathology</i> , 2010, 57, 233-243.	2.9	27
167	Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. <i>Oncotarget</i> , 2010, 1, 651-661.	1.8	272
168	TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. <i>PLoS ONE</i> , 2010, 5, e14282.	2.5	52
169	Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). <i>Pathology</i> , 2010, 42, 229-234.	0.6	21
170	Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. <i>Lung Cancer</i> , 2010, 68, 192-197.	2.0	13
171	Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. <i>Human Pathology</i> , 2010, 41, 70-78.	2.0	24
172	The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. <i>European Journal of Cancer</i> , 2010, 46, 2304-2313.	2.8	76
173	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. <i>Leukemia and Lymphoma</i> , 2010, 51, 199-212.	1.3	88
174	Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 4823.	3.3	45
175	ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 732.	3.3	46
176	Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. <i>International Journal of Cancer</i> , 2009, 124, 2116-2123.	5.1	76
177	The prognostic value of cytology and fluorescence <i>in situ</i> hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. <i>International Journal of Cancer</i> , 2009, 124, 2899-2904.	5.1	98
178	HOX D13 expression across 79 tumor tissue types. <i>International Journal of Cancer</i> , 2009, 125, 1532-1541.	5.1	53
179	Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. <i>Cancer</i> , 2009, 115, 4021-4029.	4.1	46
180	Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. <i>Histopathology</i> , 2009, 55, 564-575.	2.9	46

#	ARTICLE	IF	CITATIONS
181	Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors. <i>World Journal of Gastroenterology</i> , 2009, 15, 5898.	3.3	107
182	Combined Histomorphologic and Immunohistochemical Phenotype to Predict the Presence of Vascular Invasion in Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1114-1121.	1.3	12
183	Prognostic Significance of Protein Markers in Colorectal Cancer Stratified by Mismatch Repair Status. , 2009, , 227-240.		0
184	KIT, PDGFR α and EGFR analysis in nephroblastoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 637-650.	2.8	6
185	Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 579-588.	2.8	14
186	Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. <i>Cancer</i> , 2008, 112, 495-502.	4.1	58
187	Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. <i>Modern Pathology</i> , 2008, 21, 1403-1412.	5.5	120
188	Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma?. <i>Human Pathology</i> , 2008, 39, 1527-1534.	2.0	24
189	S2041 Biological Marker Expression Selects a Subgroup of Early Rectal Cancer Patients for Pre-Operative Therapy. <i>Gastroenterology</i> , 2008, 134, A-303.	1.3	0
190	S2040 Tumor Infiltrating Lymphocytes and RHAMM Expression Predict Prognosis in Patients with Rectal Cancer. <i>Gastroenterology</i> , 2008, 134, A-303.	1.3	0
191	Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. <i>Clinical Cancer Research</i> , 2008, 14, 143-148.	7.0	69
192	RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis. <i>Clinical Cancer Research</i> , 2008, 14, 3798-3806.	7.0	46
193	Clinical Significance of Cell Cycle and Apoptosis-Related Markers in Biliary Tract Cancer. <i>American Journal of Clinical Pathology</i> , 2008, 130, 780-786.	0.7	45
194	Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2008, 14, 3792-3797.	7.0	44
195	Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 52-57.	1.7	31
196	Loss of Raf-1 Kinase Inhibitor Protein Expression Is Associated With Tumor Progression and Metastasis in Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2007, 127, 820-827.	0.7	119
197	Prognostic Value of Cell Cycle and Apoptosis Regulatory Proteins in Mismatch Repair-Proficient Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2007, 127, 114-123.	0.7	25
198	Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. <i>Journal of Clinical Pathology</i> , 2007, 60, 1112-1116.	2.0	197

#	ARTICLE	IF	CITATIONS
199	Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor- β^2 pathway. <i>European Journal of Cancer</i> , 2007, 43, 624-631.	2.8	57
200	Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. <i>European Journal of Cancer</i> , 2007, 43, 1101-1107.	2.8	60
201	Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. <i>Modern Pathology</i> , 2007, 20, 331-338.	5.5	69
202	Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 763-769.	2.8	70
203	Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer: A tissue microarray-based approach. <i>Human Pathology</i> , 2006, 37, 1022-1031.	2.0	40
204	Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. <i>Modern Pathology</i> , 2006, 19, 1236-1242.	5.5	72
205	Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. <i>Modern Pathology</i> , 2006, 19, 1302-1309.	5.5	51
206	The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. <i>Cancer</i> , 2006, 106, 284-286.	4.1	22
207	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. <i>Cancer</i> , 2005, 104, 2517-2521.	4.1	48
208	A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods. <i>Clinical Cancer Research</i> , 2005, 11, 5440-5443.	7.0	46
209	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8